Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6253b6ac4e7d2396ea1aef04d3ccd6c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e9bd1d65a6aacbb0eee1d0962dd01e2 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2009-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b94a1a91b12e15548176003d7ff3084 |
publicationDate |
2012-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2012107319-A1 |
titleOfInvention |
Pharmaceutical compositions comprising antibodies binding to the intracellular domain of EBV (Epstein-Barr virus) latent membrane protein-1 (LMP1) |
abstract |
The invention relates to pharmaceutical and vaccine compositions comprising an antibody binding specifically to the intracellular domain of EBV protein LMP1. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018026911-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11369635-B2 |
priorityDate |
2008-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |